Bayer has been granted a patent for a compound with potential in treating cardiovascular, ophthalmic disorders, and inhibiting plasma kallikrein activity. The compound, 5-({6-amino-244-(5-chloro-2-cyanophenyl)-5-methoxy-2-oxopyridin-1 (2H)-yl]-3-methylhexanoyl} amino)pyrazolo[1,5-a]pyridine-3-carboxamide, is aimed at therapeutic and prophylactic use. GlobalData’s report on Bayer gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Bayer AG - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Bayer, Peptide pharmacophores was a key innovation area identified from patents. Bayer's grant share as of January 2024 was 57%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11884660B2) discloses a compound with the chemical formula 5-({6-amino-2-[4-(5-chloro-2-cyanophenyl)-5-methoxy-2-oxopyridin-1 (2H)-yl]-3-methylhexanoyl} amino)pyrazolo[1,5-a]pyridine-3-carboxamide, which is claimed to have potential therapeutic applications. The patent also includes variations of the compound, such as the salt 5-({6-amino-2-[4-(5-chloro-2-cyanophenyl)-5-methoxy-2-oxopyridin-1 (2H)-yl]-3-methylhexanoyl} amino)pyrazolo[1,5-a]pyridine-3-carboxamide trifluoroacetate.

Furthermore, the patent claims the use of the compound for the treatment of thrombotic or thromboembolic disorders, both in vivo and ex vivo. It also discloses methods for preventing coagulation in organ transplantation, blood banking, and biological sample preservation by administering the compound in effective amounts. The inclusion of pharmaceutically suitable excipients in a medicament containing the compound is also claimed in the patent, indicating its potential for formulation into a therapeutic product for clinical use.

To know more about GlobalData’s detailed insights on Bayer, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies